Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Age
0 - 18 years
Sex
ALL
Healthy Volunteers
No
Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University
Beijing, China
Start Date
June 30, 2024
Primary Completion Date
April 30, 2027
Completion Date
July 31, 2027
Last Updated
December 3, 2025
30
ESTIMATED participants
Hetrombopag
DRUG
Lead Sponsor
Beijing Children's Hospital
NCT04936529
NCT06541262
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04851119